+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PD-1 & PD-L1 Inhibitors Market by Product Type, Indication, End User, Distribution Channel, Route Of Administration, Company - Global Forecast to 2030- Product Image
PD-1 & PD-L1 Inhibitors Market by Product Type, Indication, End User, Distribution Channel, Route Of Administration, Company - Global Forecast to 2030- Product Image
Sale

PD-1 & PD-L1 Inhibitors Market by Product Type, Indication, End User, Distribution Channel, Route Of Administration, Company - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674438
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The PD-1 & PD-L1 Inhibitors Market grew from USD 44.61 billion in 2024 to USD 53.91 billion in 2025. It is expected to continue growing at a CAGR of 20.69%, reaching USD 137.93 billion by 2030.

Unleashing the Potential of PD-1 and PD-L1 Therapeutics

The discovery of immune checkpoint inhibitors targeting PD-1 and PD-L1 has ushered in a new era in cancer therapy, fundamentally altering treatment paradigms and patient outcomes. By unleashing the inherent power of the immune system to recognize and eliminate tumor cells, these agents have demonstrated durable responses across multiple malignancies, redefining standards of care.

Since their clinical introduction, PD-1 and PD-L1 inhibitors have expanded rapidly from monotherapy regimens to combination protocols with chemotherapy, targeted agents, and novel immune modulators. This evolution underscores the adaptability and transformative potential of checkpoint blockade, as oncology professionals integrate these therapies to address high-unmet needs in diseases ranging from lung cancer to melanoma.

Against this backdrop of innovation, understanding the nuanced dynamics of drug portfolios, regional adoption, and competitive activity becomes essential for decision-makers. This executive summary distills the most critical insights on therapeutic differentiation, market drivers, and strategic imperatives to help industry leaders navigate a complex landscape and unlock future growth opportunities.

Revolutionary Shifts Charting a New Immunotherapy Paradigm

The immuno-oncology landscape is in the midst of a paradigm shift, driven by groundbreaking clinical data, evolving regulatory frameworks, and the integration of artificial intelligence in drug discovery. Recent pivotal trials have expanded indications for both PD-1 and PD-L1 inhibitors, extending their reach into earlier lines of therapy, neoadjuvant settings, and novel combination regimens.

Simultaneously, regulatory authorities have accelerated approval pathways and issued preferential designations, reflecting confidence in the robust safety and efficacy profiles of checkpoint inhibitors. These shifts have catalyzed a surge of pipeline activity, as both established pharmaceutical giants and emerging biotech firms pursue next-generation molecules, bispecific antibodies, and adaptive cell therapies designed to overcome resistance mechanisms.

Complementing clinical and regulatory momentum, advancements in biomarker-driven patient selection are redefining therapeutic positioning. Precision diagnostics, encompassing tumor mutational burden and PD-L1 expression panels, now inform tailored treatment algorithms. As a result, the competitive arena is intensifying, with stakeholders prioritizing value-based pricing and real-world evidence to substantiate clinical benefits and secure market access.

Assessing the 2025 US Tariff Wave and Its Impacts on Access

The scheduled tariff adjustments in 2025 have emerged as a critical factor influencing pricing structures, supply chain logistics, and market access strategies within the United States. By imposing incremental duties on imported therapeutic agents and active pharmaceutical ingredients, these measures introduce a layer of complexity for manufacturers and payers alike.

Proactive scenario planning has become imperative, as biopharma leaders evaluate the cascading effects of increased input costs on negotiated contracts with healthcare providers and pharmacy benefit managers. Manufacturers are reassessing sourcing strategies, exploring domestic partnerships for drug substance production, and investing in supply chain resilience to mitigate exposure to tariff volatility.

Moreover, the evolving policy environment has galvanized stakeholder collaboration, prompting industry associations and advocacy groups to engage with policymakers in pursuit of harmonized solutions. Transparent communication across the value chain serves to align expectations, preserve patient access, and sustain investment in research and development despite the headwinds posed by new trade measures.

Dissecting Market Segmentation to Illuminate Growth Drivers

An in-depth segmentation lens reveals that product type dynamics are central to market trajectories. PD-1 inhibitors, notably Cemiplimab, Nivolumab, and Pembrolizumab, have established leadership positions attributable to their broad clinical portfolios and robust post-marketing data. Meanwhile, PD-L1 inhibitors such as Atezolizumab, Avelumab, and Durvalumab continue to carve out differentiated niches through novel dosing regimens and combination strategies.

Indication-based segmentation underscores lung cancer as the most contested territory, given its high incidence and established biomarker frameworks. Melanoma and renal cell carcinoma follow closely, where long-term survival data has fortified the role of checkpoint blockade. Less crowded but strategically valuable pockets-bladder cancer and head and neck cancer-offer expansion pathways for late-stage pipeline entrants.

End-user segmentation highlights the dominant role of hospital settings in administering intravenous formulations, while specialty clinics drive early adoption of subcutaneous delivery options. Distribution channel segmentation points to hospital pharmacies as the primary fulfillment route, complemented by growing online and retail pharmacy engagement spurred by patient convenience initiatives. Route of administration segmentation further differentiates the market as subcutaneous formulations gain traction, supported by patient-centric dosing and healthcare provider efficiencies.

Company-level segmentation maps a competitive tableau dominated by AstraZeneca, Bristol-Myers Squibb, Merck & Co., and Roche. These incumbents leverage expansive R&D infrastructures and global commercialization networks, compelling emerging players to forge alliances or pursue niche differentiation to gain market entry.

Regional Dynamics Shaping Global Immunotherapy Adoption

Regional analysis illuminates profound disparities in access, reimbursement policies, and adoption curves. In the Americas, established healthcare infrastructures and favorable reimbursement frameworks have accelerated uptake of PD-1 and PD-L1 inhibitors, making the region a bellwether for broader market trends.

Shifting to Europe, Middle East & Africa, heterogeneous regulatory landscapes yield a patchwork of access scenarios. Western European markets benefit from centralized approval mechanisms and cost-effectiveness evaluations, whereas certain EMEA territories face budgetary constraints that temper rapid adoption. Nonetheless, strategic pricing initiatives and outcome-based agreements are gaining traction as stakeholders seek sustainable reimbursement models.

Across Asia-Pacific, dynamic demographic shifts and rising cancer incidence rates have rendered the region a critical arena for future growth. Markets such as Japan and Australia exhibit mature immunotherapy ecosystems, while emerging economies in Southeast Asia and India present high-growth potential conditioned on expanding diagnostic infrastructure and evolving payer policies. These regional nuances demand tailored market entry and portfolio management strategies to maximize penetration and patient impact.

Competitive Landscape: Strategic Moves of Leading Innovators

Analysis of leading corporations reveals distinct strategic approaches to maintain and extend leadership in checkpoint inhibition. AstraZeneca has prioritized strategic collaborations and late-stage pipeline diversification to reinforce its immuno-oncology franchise. Bristol-Myers Squibb continues to leverage its first-mover advantage in PD-1 inhibition, while investing in next-generation constructs designed to overcome primary resistance.

Merck & Co. sustains momentum through robust real-world evidence generation and high-impact clinical trial publications that solidify Pembrolizumab’s role in multiple treatment algorithms. Roche has pursued targeted combination regimens, integrating its diagnostics portfolio to drive companion testing adoption alongside therapeutic deployment.

Emerging contenders deploy focused innovation and agile trial designs to address underserved indications and optimize delivery modalities. This competitive mosaic underscores the critical importance of differentiated clinical data, strategic partnerships, and nimble commercialization models for companies aiming to disrupt established hierarchies.

Strategic Imperatives for Industry Leaders in Immuno-Oncology

Industry leaders must prioritize integrated portfolio strategies that align novel checkpoint inhibitors with biomarker-driven patient selection. By investing in translational research and advancing precision diagnostics, organizations can enhance efficacy outcomes and secure premium reimbursement.

Partnerships with manufacturing specialists are essential to fortify supply chain resilience amid evolving trade policies and optimize cost structures. Concurrently, developing subcutaneous and next-generation formulations will address healthcare provider preferences and improve patient adherence, differentiating offerings in a crowded market.

Engagement with payers through risk-sharing agreements and outcome-based contracting can establish value recognition and expedite market entry. Real-world data initiatives should be scaled to demonstrate long-term benefits, thereby reinforcing pricing strategies and mitigating reimbursement barriers.

Finally, leveraging digital platforms for patient support programs and remote monitoring can enhance adherence, generate engagement insights, and foster loyalty, driving sustained uptake of immuno-oncology agents across diverse care settings.

Rigorous Methodology Underpinning Robust Market Insights

This report’s findings derive from a robust, multi-phase research approach combining primary and secondary intelligence. In-depth interviews with oncologists, payers, and supply chain experts furnished qualitative perspectives on clinical adoption, reimbursement dynamics, and logistical challenges.

Extensive analysis of regulatory filings, peer-reviewed literature, and clinical trial registries provided a comprehensive foundation for mapping therapeutic trends and comparative efficacy. Proprietary databases and market transaction records were leveraged to validate competitive positioning and deal flow activity.

Our methodology integrates triangulation techniques to corroborate data points, ensuring consistency and reliability. The synthesis of segment-specific insights with macroeconomic and policy analyses underpins the report’s strategic frameworks. This rigorous process guarantees that stakeholders receive actionable, evidence-based guidance tailored to the complexities of the PD-1 and PD-L1 inhibitor markets.

Synthesis of Insights Fueling the Future of Immunotherapy

The convergence of clinical innovation, regulatory evolution, and strategic competition is reshaping the immunotherapy landscape at an unprecedented pace. Decision-makers armed with deep segmentation insights, regional intelligence, and an understanding of tariff implications will be best positioned to capitalize on emerging opportunities.

The leaders of tomorrow will be those who anticipate market shifts, forge collaborative partnerships across the value chain, and invest in next-generation modalities that address unmet needs. By applying the strategic imperatives outlined here, stakeholders can navigate complexity, secure sustainable growth, and ultimately improve patient outcomes in the fight against cancer.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • PD-1 Inhibitor
      • Cemiplimab
      • Nivolumab
      • Pembrolizumab
    • PD-L1 Inhibitor
      • Atezolizumab
      • Avelumab
      • Durvalumab
  • Indication
    • Bladder Cancer
    • Head And Neck Cancer
    • Lung Cancer
    • Melanoma
    • Renal Cell Carcinoma
  • End User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Route Of Administration
    • Intravenous
    • Subcutaneous
  • Company
    • AstraZeneca
    • Bristol-Myers Squibb
    • Merck & Co.
    • Roche
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck KGaA
  • Pfizer Inc.
  • BeiGene, Ltd.
  • Innovent Biologics, Inc.
  • CStone Pharmaceuticals
  • Shanghai Junshi Biosciences Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PD-1 & PD-L1 Inhibitors Market, by Product Type
8.1. Introduction
8.2. PD-1 Inhibitor
8.2.1. Cemiplimab
8.2.2. Nivolumab
8.2.3. Pembrolizumab
8.3. PD-L1 Inhibitor
8.3.1. Atezolizumab
8.3.2. Avelumab
8.3.3. Durvalumab
9. PD-1 & PD-L1 Inhibitors Market, by Indication
9.1. Introduction
9.2. Bladder Cancer
9.3. Head And Neck Cancer
9.4. Lung Cancer
9.5. Melanoma
9.6. Renal Cell Carcinoma
10. PD-1 & PD-L1 Inhibitors Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Research Institutes
10.4. Specialty Clinics
11. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. PD-1 & PD-L1 Inhibitors Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Subcutaneous
13. PD-1 & PD-L1 Inhibitors Market, by Company
13.1. Introduction
13.2. AstraZeneca
13.3. Bristol-Myers Squibb
13.4. Merck & Co.
13.5. Roche
14. Americas PD-1 & PD-L1 Inhibitors Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa PD-1 & PD-L1 Inhibitors Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific PD-1 & PD-L1 Inhibitors Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Bristol-Myers Squibb Company
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. AstraZeneca PLC
17.3.5. Merck KGaA
17.3.6. Pfizer Inc.
17.3.7. BeiGene, Ltd.
17.3.8. Innovent Biologics, Inc.
17.3.9. CStone Pharmaceuticals
17.3.10. Shanghai Junshi Biosciences Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PD-1 & PD-L1 INHIBITORS MARKET MULTI-CURRENCY
FIGURE 2. PD-1 & PD-L1 INHIBITORS MARKET MULTI-LANGUAGE
FIGURE 3. PD-1 & PD-L1 INHIBITORS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 59. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 60. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 65. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 67. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 68. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 106. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 108. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 109. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 114. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 116. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 117. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 130. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 132. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 133. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 138. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 140. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 141. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 170. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 172. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 173. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. DENMARK PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 186. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 188. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 189. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. QATAR PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 194. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 196. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 197. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. FINLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 218. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 220. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 221. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. EGYPT PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 226. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 228. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 229. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. TURKEY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 242. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 244. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 245. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. NORWAY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 250. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 252. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 253. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. POLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 275. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 277. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 278. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 279. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. CHINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 283. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 285. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 286. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 287. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. INDIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 291. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 293. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 294. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 295. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. JAPAN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2030 (USD MILLION)
TABLE 323. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 324. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 325. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2030 (USD MILLION)
TABLE 326. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 327. THAILAND PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. THAILAND PD-1 & PD-L1 INHIBITORS MARKE

Companies Mentioned

The companies profiled in this PD-1 & PD-L1 Inhibitors market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck KGaA
  • Pfizer Inc.
  • BeiGene, Ltd.
  • Innovent Biologics, Inc.
  • CStone Pharmaceuticals
  • Shanghai Junshi Biosciences Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 53.91 Billion
Forecasted Market Value ( USD ) by 2030 $ 137.93 Billion
Compound Annual Growth Rate20.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

PD-1 and PD-L1 Inhibitors - Global Strategic Business Report - Product Image

PD-1 and PD-L1 Inhibitors - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
PD-1 And PD-L1 Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

PD-1 And PD-L1 Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 160 Pages
  • Global
From
PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025 - Product Image

PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025 - Product Image

PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025

  • Report
  • 400 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors Market 2024-2028 - Product Image

PD-1 and PD-L1 Inhibitors Market 2024-2028

  • Report
  • 136 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.